Isabel Roels-Leroux

Gent, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus.

From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus.

Journal: Expert review of vaccines

Published: June 08, 2026

Correction: Leroux-Roels et al. Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. Vaccines 2026, 14, 146.

Correction: Leroux-Roels et al. Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. Vaccines 2026, 14, 146.

Journal: Vaccines

Published: May 06, 2026

Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.

Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.

Journal: The New England journal of medicine

Published: May 06, 2026

A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults.

A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults.

Journal: Human vaccines & immunotherapeutics

Published: March 03, 2026

Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.

Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.

Journal: Human vaccines & immunotherapeutics

Published: February 17, 2026

Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial.

Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 30, 2026

Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study.

Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study.

Journal: Vaccines

Published: December 22, 2025

Induction of a Th1-Type Polyfunctional T-Cell Response by the Four-segmented Rift Valley Fever Candidate Vaccine in Humans.

Induction of a Th1-Type Polyfunctional T-Cell Response by the Four-segmented Rift Valley Fever Candidate Vaccine in Humans.

Journal: The Journal of infectious diseases

Published: December 19, 2025

Microbiological contamination of nursing mobile workstations: assessing their role in pathogen transmission in healthcarefacilities.

Microbiological contamination of nursing mobile workstations: assessing their role in pathogen transmission in healthcarefacilities.

Journal: Infection prevention in practice

Published: December 15, 2025

Infection, vaccination and risk of dementia: a proposed immunological model.

Infection, vaccination and risk of dementia: a proposed immunological model.

Journal: Frontiers in immunology

Published: November 17, 2025

A Novel Carbohydrate Fatty-Acid Monosulphate Ester, Squalane-in-Water Adjuvant Is Safe and Enhances Inactivated Influenza Vaccine Immunogenicity in Older Adults.

A Novel Carbohydrate Fatty-Acid Monosulphate Ester, Squalane-in-Water Adjuvant Is Safe and Enhances Inactivated Influenza Vaccine Immunogenicity in Older Adults.

Journal: Vaccines

Published: July 28, 2025

A standardized workflow for typing S. marcescens outbreaks using FT-IR spectroscopy.

A standardized workflow for typing S. marcescens outbreaks using FT-IR spectroscopy.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: July 10, 2025

Showing 1-12 of 86

Last Updated: 09/26/2026